A single intravenous infusion of Lilly's investigational base editor VERVE‑102 produced dose-dependent reductions in PCSK9 of up to 88 per cent and LDL cholesterol of up to 62 per cent, with effects sustained for up to 18 months. …
Single infusion of Lilly gene editing cuts cholesterol with the company planning long-term study
May 27, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Australians want more from healthcare as convenience, prevention and fragmentation reshape care
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News -
Neurizon secures GMP supply of monepantel to strengthen NUZ 001 commercial readiness
June 17, 2026 - - Australian Biotech -
Percheron completes HMBD-002 drug substance manufacture
June 17, 2026 - - Australian Biotech -
Racura completes significant fund raise to advance three clinical trials
June 17, 2026 - - Australian Biotech -
Novartis names interim leader for Australia and NZ after Country President departs
June 17, 2026 - - Latest News